Drug
Mecasermin
Mecasermin: highest development phase Phase 2/3, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| mecasermin NCT00571727 | Phase 2/3 | Growth Hormone Insensitivity Syndrome |
Latest
No recent events.
Follow Mecasermin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.